ENESDENewsletter →
Shotlee
Get the app
📖Complete Guide✅Updated 2026🔬Evidence-Based

PF-08653944 Guide

Pfizer Monthly GLP-1 Pill 2026

Complete guide to PF-08653944 — Pfizer

Download on theApp Store
Get it onGoogle Play
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
Pf 08653944B12
PF 08653944
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Pf 08653944
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
Pf 08653944Retatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
Pf 08653944B12
PF 08653944
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Pf 08653944
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
Pf 08653944Retatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01BACKGROUND

What Is PF-08653944 Guide?

PF-08653944 represents Pfizer\'s second attempt at an oral GLP-1 small molecule after danuglipron was discontinued due to tolerability concerns. A small molecule GLP-1 agonist differs fundamentally from peptide-based options like semaglutide tablets (Rybelsus/oral Wegovy) — small molecules don\'t require the SNAC absorption workaround, can be engineered for extended-release profiles, and can potentially achieve once-weekly or once-monthly dosing. The once-monthly profile would be a historic breakthrough in GLP-1 therapy — dramatically improving adherence compared to daily or weekly medications.

02MECHANICS

Key Biohacking Mechanics

1
Directly activates GLP-1 receptors like semaglutide
2
Does NOT require SNAC delivery technology
3
Oral bioavailability via conventional absorption
4
No injection training or refrigeration needed
5
Extended-release oral formulation
6
Single pill per month — historic if approved
7
Eliminates weekly injection burden
8
Dramatically improves adherence potential
9
9.3% body weight loss at highest dose
10
Meaningful reduction vs placebo
11
Better GI tolerability than prior Pfizer candidates
12
Phase 2 completion targeted 2025
13
No fasting requirement (unlike semaglutide tablet)
14
No 30-min timing window post-dose
15
True once-monthly vs once-daily
16
Potential for better compliance long-term
03DEEP DIVE

Expected Dosing Schedule

Starting dose establishing safety profile

Dose-response exploration

9.3% weight loss achieved at highest dose

Target once-monthly pill — unique in GLP-1 class

Note: Final approved dosing may vary. Follow your prescriber's guidance. Use Shotlee to log each weekly dose and monitor your progress.

04WHAT TO TRACK

Side Effects

01
⚠️
GI Side Effects
Nausea (class effect of GLP-1 agonism). Vomiting. Constipation. Fatigue at peak plasma levels. Dose-escalation may reduce severity
02
🔬
Improved Over Danuglipron
Better tolerability vs previous Pfizer candidate. Lower GI discontinuation rates in Phase 2. Extended-release design reduces peak concentration. Still under investigation — Phase 3 data pending. Not y
05TIMELINE

Development Timeline

2022-2023:
Danuglipron Phase 2 — discontinued due to tolerability (2x daily dosing issues)
2024:
PF-08653944 Phase 2 initiated — improved once-monthly profile
2025:
Phase 2 data readout and potential Phase 3 decision
2026-2027:
Phase 3 enrollment expected if Phase 2 data is positive
06WHAT TO TRACK

Vital Protocol FAQs

01
🔬
Is PF-08653944 the same as danuglipron?
No — danuglipron was Pfizer\'s first oral GLP-1 small molecule (taken twice daily) that was discontinued due to liver toxicity concerns in some patients and poor tolerability. PF-08653944 is a distinc
02
🧬
How does PF-08653944 compare to orforglipron?
Orforglipron (Eli Lilly\'s oral small molecule GLP-1) is taken once daily and shows ~15% weight loss. PF-08653944 targets once-monthly dosing at ~9.3% weight loss — less effective but potentially much
03
📱
Can I use Shotlee to track oral GLP-1 medications?
Yes — Shotlee supports tracking any GLP-1 medication including oral formulations. Log daily or monthly doses, monitor weight loss progress, and track side effects effortlessly.
07FAQ

Guide FAQs

Complete guide to PF-08653944 — Pfizer

Yes. Shotlee supports tracking Pf 08653944 doses, side effects, and health metrics. It is free to use.

Free · Always

Track Your Pf 08653944 Protocol in Shotlee

Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.

Download on theApp Store
Get it onGoogle Play

📚References & sources

🔗Keep exploring

All Guides
→
Trackers
→
Compare
→
Start tracking